Ronac Mamtani, MD, MSCE
Associate Professor of Medicine (Hematology-Oncology) at the Hospital of the University of Pennsylvania
Attending Physician, Hematology-Oncology, Hospital of the University of Pennsylvania
Department: Medicine
Contact information
Division of Hematology Oncology
Perelman Center for Advanced Medicine
10th Floor, South Pavilion
Office #10-308
3400 Civic Center Blvd
Philadelphia, PA 19147
Perelman Center for Advanced Medicine
10th Floor, South Pavilion
Office #10-308
3400 Civic Center Blvd
Philadelphia, PA 19147
Office: 2156627606
Fax: (215) 349-8551
Fax: (215) 349-8551
Email:
ronac.mamtani@uphs.upenn.edu
ronac.mamtani@uphs.upenn.edu
Education:
BS
Cornell University, 2002.
MD (Internal Medicine)
Stony Brook School of Medicine, 2006.
MS (Clinical Epidemiology)
University of Pennsylvania , 2012.
Permanent linkBS
Cornell University, 2002.
MD (Internal Medicine)
Stony Brook School of Medicine, 2006.
MS (Clinical Epidemiology)
University of Pennsylvania , 2012.
Selected Publications
Chow RD, Mamtani R.: Assessment of synergistic vs. independent drug activity for enfortumab vedotin and pembrolizumab in untreated advanced urothelial carcinoma. Urol Oncol Aug 2025.Parikh RB, Ulloa-Pérez E, Kurian M, Hubbard R, Joffe S, Lynch HF, Mamtani R.: Prescribing Changes After Accelerated vs Regular Approval of Oncology Therapies. JAMA Netw Open 8: e2520726, Jul 2025.
Lian Y, Voruganti T, Lu J, Long Q, Mamtani R.: Survival Trends in Urothelial Cancer Before and After ICIs and Antibody Drug Conjugates. JAMA Netw Open 8: e2519524, Jul 2025.
Reibel JB, Sun LL, Parikh RB, Mahmud N, Martin LP, Hubbard RA, Mamtani R.: Real-world impact of the platinum chemotherapy shortage on US patients with advanced cancer. J Natl Cancer Inst 117: 1276-1278, Jun 2025.
Swami N, Hwang WT, Mamtani R, O'Hara MH, Chapin WJ.: Second-Line Treatment Strategies for Right-Sided, RAS/RAF Wild-Type Colorectal Cancer. JAMA Netw Open 8(6): e2515087, Jun 2025.
Barsouk AA, Yang A, Sussman JH, Elghawy O, Xu J, Xu J, Meng L, Koga S, Du W, Mamtani R, Mei L.: Survival Disparities by Sex, Race, and Age in the Era of Contemporary Advanced Urothelial Carcinoma Therapy: A Real-World Analysis. Clin Genitourin Cancer 23: 102395, Jun 2025.
Kurian M, Nimgaonkar V, Elghawy O, Mamtani R.: Real-world enfortumab vedotin +/- pembrolizumab (EV+/-P)–based treatment toxicity, treatment discontinuation, and associations with survival in advanced urothelial carcinoma (aUC). American Society of Clinical Oncology Annual Meeting I 2025, Chicago, IL. Poster Presentation. 43(16), May 2025.
Kurian M, Ferrell WJ, Ulloa Perez E, Hubbard R, Joffe S, Mamtani R*, Parikh RB, Lynch HF.: Specificity of Food and Drug Administration postmarketing requirements and associations with timely submissions and regulatory decisions for oncology accelerated approvals, 2011-2023: a cross-sectional analysis. BMJ Oncol 4(1): e000659, May 2025 Notes: *Co-senior author.
Wang X, Long JB, Rothen J, Huang S, Soulos P, Robinson TJ, Presley CJ, Goldberg SB, Mamtani R, Ma SM, Wang SY, Dinan MA, Gross CP. : Use of targeted therapy in patients with advanced non-small cell lung cancer in response to broad genomic profiling. American Society of Clinical Oncology Annual Meeting I 2025, Chicago IL. Poster Presentation. 43(16), May 2025 Notes: Poster.
Wang X, Rothen J, Huang S, Long JB, Soulos PR, Goldberg SB, Mamtani R, Presley CJ, Kunst N, Ma S, Wang SY, Gross CP, Dinan MA.: Adoption of Broad Genomic Profiling in Patients With Cancer. JAMA Oncol Apr 2025.